AU7612100A - Systems and methods for opening obstructed biological conduits - Google Patents

Systems and methods for opening obstructed biological conduits

Info

Publication number
AU7612100A
AU7612100A AU76121/00A AU7612100A AU7612100A AU 7612100 A AU7612100 A AU 7612100A AU 76121/00 A AU76121/00 A AU 76121/00A AU 7612100 A AU7612100 A AU 7612100A AU 7612100 A AU7612100 A AU 7612100A
Authority
AU
Australia
Prior art keywords
conduit
obstruction
methods
systems
enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU76121/00A
Other languages
English (en)
Inventor
Nicholas F. Franano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of AU7612100A publication Critical patent/AU7612100A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/486—Elastase (3.4.21.36 or 3.4.21.37)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Materials For Medical Uses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Processing Of Meat And Fish (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU76121/00A 1999-09-24 2000-09-24 Systems and methods for opening obstructed biological conduits Abandoned AU7612100A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15593899P 1999-09-24 1999-09-24
US60155938 1999-09-24
PCT/US2000/026237 WO2001021574A1 (en) 1999-09-24 2000-09-24 Systems and methods for opening obstructed biological conduits

Publications (1)

Publication Number Publication Date
AU7612100A true AU7612100A (en) 2001-04-24

Family

ID=22557384

Family Applications (1)

Application Number Title Priority Date Filing Date
AU76121/00A Abandoned AU7612100A (en) 1999-09-24 2000-09-24 Systems and methods for opening obstructed biological conduits

Country Status (11)

Country Link
EP (4) EP2332568A1 (enExample)
JP (2) JP5763286B2 (enExample)
AT (2) ATE361095T1 (enExample)
AU (1) AU7612100A (enExample)
CA (1) CA2385488C (enExample)
CY (3) CY1106656T1 (enExample)
DE (1) DE60034694T2 (enExample)
DK (3) DK1923068T3 (enExample)
ES (3) ES2364191T3 (enExample)
PT (3) PT1220830E (enExample)
WO (1) WO2001021574A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063838B1 (en) 1999-09-24 2006-06-20 Proteon Therapeutics Llc Methods for treating an artery or vein in a human subject
WO2004073504A2 (en) 2003-02-20 2004-09-02 Proteon Therapeutics, Llc Methods for the treatment and prevention of diseases of biological conduits
JP2008513517A (ja) * 2004-09-22 2008-05-01 プロテオン セラペウチクス インコーポレーテッド 生物学的導管の疾患の治療方法及び予防方法
US10071143B1 (en) 2007-05-03 2018-09-11 The Research Foundation For The State University Of New York Methods for non-surgical treatment of carpal tunnel syndrome
US8501449B2 (en) * 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof
EP4015627B1 (en) 2012-01-12 2023-09-27 Endo Global Ventures Clostridium histolyticum enzyme
US9636385B2 (en) 2012-10-24 2017-05-02 The Research Foundation For The State University Of New York Use of collagenase to treat glaucoma
KR20230003601A (ko) 2017-03-01 2023-01-06 엔도 벤쳐즈 리미티드 셀룰라이트를 평가하고 치료하기 위한 장치 및 방법
KR20240001279A (ko) 2017-03-28 2024-01-03 엔도 벤쳐즈 리미티드 개선된 콜라게나제 생성 방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489261A (en) * 1981-01-26 1996-02-06 Trustees Of Boston University Hydrogels capable of supporting cell growth
US4636195A (en) * 1982-04-02 1987-01-13 Harvey Wolinsky Method and apparatus for removing arterial constriction
US4803294A (en) * 1987-10-29 1989-02-07 G. D. Searle & Co. Process and intermediates for the preparation of halogenated protease inhibitors
JPH0286777A (ja) * 1988-09-22 1990-03-27 Sankyo Co Ltd サル膵臓エラスターゼｉ
DK0456724T3 (da) * 1989-01-27 1995-10-02 Immunolytics Inc Præparat og fremgangsmåde til behandling af benign prostatisk hypertrofi
US5116615A (en) * 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
NL8900943A (nl) * 1989-04-14 1990-11-01 Euro Biopharm Technology B V Protease inhibitor.
US5318531A (en) * 1991-06-11 1994-06-07 Cordis Corporation Infusion balloon catheter
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5422261A (en) * 1993-04-16 1995-06-06 Baxter International Inc. Composition containing collagenase and chymopapain for hydrolyzing connective tissue to isolate cells
US5409926A (en) 1993-07-19 1995-04-25 Merck & Co., Inc. AT-2 antagonist inhibition of vascular restenosis
WO1996018725A1 (en) * 1994-12-13 1996-06-20 Human Genome Sciences, Inc. Human tissue inhibitor of metalloproteinase-4
US6020181A (en) * 1995-05-17 2000-02-01 New York Blood, Inc. Inhibition of thrombus formation by medical related apparatus comprising treating with fibrinolytic matrix metalloproteinase
US5830468A (en) * 1995-05-17 1998-11-03 The New York Blood Center, Inc. Fibrin(ogen) degradation by fibrinolytic matrix metalloproteinase
US5834449A (en) * 1996-06-13 1998-11-10 The Research Foundation Of State University Of New York Treatment of aortic and vascular aneurysms with tetracycline compounds
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors

Also Published As

Publication number Publication date
DK2363142T3 (en) 2015-04-20
DK1923068T3 (da) 2011-06-27
JP5793461B2 (ja) 2015-10-14
DK1220830T3 (da) 2007-07-16
DE60034694T2 (de) 2008-01-17
PT1923068E (pt) 2011-07-29
EP1220830A4 (en) 2005-03-30
PT1220830E (pt) 2007-06-11
WO2001021574A9 (en) 2002-12-27
EP2332568A1 (en) 2011-06-15
ES2534938T3 (es) 2015-04-30
CY1117932T1 (el) 2017-05-17
JP2012131830A (ja) 2012-07-12
WO2001021574A1 (en) 2001-03-29
ES2364191T3 (es) 2011-08-26
CA2385488C (en) 2015-07-07
EP1220830A1 (en) 2002-07-10
JP2003523319A (ja) 2003-08-05
EP2363142A9 (en) 2011-10-19
EP2363142B1 (en) 2015-03-25
EP2363142A1 (en) 2011-09-07
CY1106656T1 (el) 2012-01-25
PT2363142E (pt) 2015-08-04
EP1923068B1 (en) 2011-06-08
HK1162302A1 (en) 2012-08-31
EP1923068A1 (en) 2008-05-21
JP5763286B2 (ja) 2015-08-12
ATE361095T1 (de) 2007-05-15
DE60034694D1 (de) 2007-06-14
CA2385488A1 (en) 2001-03-29
ES2284528T3 (es) 2007-11-16
EP1220830B1 (en) 2007-05-02
CY1112329T1 (el) 2015-12-09
EP2363142B8 (en) 2015-06-10
ATE511854T1 (de) 2011-06-15

Similar Documents

Publication Publication Date Title
CY1117932T1 (el) Ελασταση για διανοιξη αποφραγμενων βιολογικων διαυλων
WO1998049972A3 (en) Differential treatment of prosthetic devices
EP1166721A3 (en) Apparatus for transvascular procedures
SE9503562D0 (sv) Kateter, särskilt för peritonealdialys
PT754072E (pt) Um dispositivo para a distribuicao local de farmacos
TW286273B (enExample)
WO2003020339A3 (en) Fluid assisted medical devices, fluid delivery systems and controllers for such devices, and methods
GR3036440T3 (en) Personal care compositions and wipe products containing the compositions
WO2002045695A3 (en) Hydrostatic delivery system for controlled delivery of agent
FR2841137B1 (fr) Systeme de vectorisation comprenant des nanoparticules de taille homogene d'au moins un polymere et d'au moins un polysaccharide charge positivement
AU7047300A (en) A high pressure and high temperature reaction system
EP0774267A3 (en) Surgical cassette adapter
AU2496199A (en) Copolymer compositions for oral delivery
PT983076E (pt) Microrganismos de degradação de oxalato ou enzimas de degradação de oxalato para prevenir doenças relacionadas com oxalato
BR0215389A (pt) Agente preventivo ou terapêutico para distúrbio urinário, método para prevenir ou tratar distúrbio urinário, uso de um composto, composto, pró-droga, processo para preparar o composto, medicamento, e, método para triar um composto
WO2000032765A3 (en) Ribozyme therapy for the treatment and/or prevention of restenosis
AU2001290468A1 (en) A device for catalytic treatment of a gas flow
CA2283129A1 (fr) Dispositif de separation de deux zones a ambiances differentes
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
AU6565900A (en) Device for washing the external auditory meatus
EP0987039A3 (en) Fluid management system
AU2185000A (en) Treatment of diseases involving cyst formation
EP0809065A3 (en) Condensate drain device
AU6429998A (en) A device for and a method of treating the inner surface of container
EP1112749A4 (en) PROPHYLAXIS OR REMEDIES FOR CIRCULATORY EYE DISTURBANCE

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase